OH-UWL
26.4.2022 19:42:09 CEST | Business Wire | Press release
UWL, a top 10 American-owned NVOCC and leading provider of global 3PL services, has contracted with Swire Shipping, a multi-purpose liner service, to launch a new, exclusive express service, departing from Ho Chi Minh City and arriving at the Port of Seattle in 18 days. Providing speed and predictability, the bi-weekly service offers the fastest trip from Vietnam to the US. This revolutionary agreement is the first dedicated ocean service by an NVOCC in the trade.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220426006070/en/
“Customers have been asking for creative solutions during this extremely challenging market, and this first-of-its-kind service is part of our response. Congestion and rate spikes will come and go, but the root issues remain. US importers are pushing for more creativity and controlled reliable solutions to manage supply chain risk,” UWL President Duncan Wright said.
The service offers priority berthing at both origin and destination, and a dedicated equipment pool for suppliers in Ho Chi Minh City. This includes 6,000 brand-new ocean containers, with 40-foot-high cube and 20-foot containers already in the rotation. Predictability is assured, as schedules are published six months in advance, with two sailings per month.
Upon arrival in Seattle, those needing warehousing or distribution space can take advantage of UWL’s sister company, World Distribution Services (WDS), and its brand-new 300,000 sq. ft. facility near Tacoma, WA, just a short drive away from the Port of Seattle.
“In joining forces with UWL, an innovative and integrated logistics provider to American BCOs, we are confident that our ocean express solution will be compelling to importers and exporters who need a direct port-to-port, fast, and reliable service between Vietnam and the Pacific Northwest,” said Rufus Frere-Smith, Regional Head, Americas, Swire Shipping, which facilitates trade in more than 90 countries and across 400 ports. “Our partnership is built on a joint vision of responding to customers’ desire for reliable, safe, and innovative shipping solutions.”
Mr. Wright noted: “We have seen incredibly strong demand for this service already, which tells us that fast and reliable niche services are here to stay. Our relationship with Swire Shipping is critical to making all this work. Their remarkable 150-year history and robust knowledge of ocean shipping and strong Asia legacy, combined with UWL’s culture of innovation, brings this dedicated service to life.”
Mr. Frere-Smith commented: “We have deployed new state-of-the-art, fuel-efficient vessels that will sail at high speed, safely and sustainably. We are confident customers and BCOs will find this direct, express service to be extremely effective in shipping their high value products and getting to market quickly.”
About UWL
UWL is a top 10 American-owned NVOCC and leading provider of global 3PL services. They take pride in delivering seamless supply chain solutions backed by a team of creative problem-solvers. Specializing in ocean transportation, air freight, road and rail, warehousing and distribution, project cargo, and customs house brokerage, their proof is in owned assets: a national network of distribution centers, dependable trucking capacity, and WorldScope , a user-friendly data management platform that delivers transparency and visibility customers can count on. Wherever your freight needs to go, they can help get it there. To find out more, visit their website at www.shipuwl.com
About Swire Shipping
Swire Shipping is a privately owned organization that was founded in 1872 and now comprises over 600 employees in 20 countries and owns and deploys over 30 vessels in the intra-Asia, Australasia, and Polynesia trades. It is part of the Swire Group which is a Hong Kong- and London-based British conglomerate. Many of its core businesses can be found within the Asia Pacific region, where traditionally Swire’s operations have centered on Hong Kong and mainland China. Its subsidiaries include Cathay Pacific Airlines, Swire Properties, China Navigation Company, Swire Hotels and Swire Resources.
About World Group
World Group was founded over 60 years ago as a pioneer in vessel agency services on the Great Lakes. Today, they are home to a portfolio of globally trusted brands that deliver customers end-to-end supply chain and logistics solutions, including ContainerPort Group, UWL, World Distribution Services, and World Shipping, Inc. With industry-leading products in ocean drayage and domestic trucking, freight forwarding and air freight, customs house brokerage, vessel husbandry, and warehousing and distribution, customers around the globe use their services to simplify supply chains and reliably move freight.
Offering career opportunities across the country for innovators in the transportation industry, their award-winning culture is anchored in people who live and breathe the company’s core values daily. Learn how to join the World Group family by visiting their careers page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220426006070/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom